單純皰疹病毒治療市場：依藥物類型、給藥途徑及地區分類

Herpes Simplex Virus Treatment Market, By Drug Type, By Route of Administration, By Geography

出版日期: 2026年03月16日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年單純皰疹病毒治療市場規模預計為28.102億美元，預計2033年將達到41.976億美元。預計2026年至2033年，該市場將以5.9%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	28.102億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	5.90%	2033年市場規模預測：	41.976億美元

單純皰疹病毒（HSV）是一種病毒感染疾病，可引起生殖器皰疹和口腔皰疹。它是一種傳染性極強的病毒。 HSV分為兩種：HSV-1和HSV-2。目前尚無治癒生殖器皰疹的治療方法，但每日服用抗病毒藥物可以預防或縮短皰疹發作的持續時間，並降低傳染他人的風險。因此，全球對根治性有效的單純皰疹病毒治療方法的需求日益成長。

市場動態

單純皰疹病毒感染疾病的日益普遍、臨床試驗數量的增加、對安全有效的 HSV治療方法的需求不斷成長以及公眾對單純皰疹病毒的認知不斷提高，預計這些因素將推動全球單純皰疹病毒治療市場在預測期內的成長。

例如，2022年10月，聯合生物製藥、上海市公共衛生臨床中心和國立成功大學微生物與免疫學系合作，研究了UB-621的療效。 UB-621是目前治療由1型和2型單純皰疹病毒（HSV-1和HSV-2）引起的生殖器皰疹的一流長效藥物。此外，世界衛生組織（WHO）及其合作夥伴組織正在支持相關研究，以開發預防和控制HSV感染疾病的新策略。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司亮點、產品系列、主要特點、財務表現和策略等參數，分析了全球單純皰疹病毒治療市場的主要參與者。
本報告中的見解將使企業負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球單純皰疹病毒治療市場報告」旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球單純皰疹病毒治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 2,810.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.90%	2033 Value Projection:	USD 4,197.6 Mn

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2022, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Market Segmentation

Global Herpes Simplex Virus Treatment Market By Drug Type (Revenue, USD Mn, 2021 - 2033)
Acyclovir
Valacyclovir
Famciclovir
Other Drugs
Global Herpes Simplex Virus Treatment Market By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Injection
Topical
Global Herpes Simplex Virus Treatment Market By Geography (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Fresenius SE & Co. KgaA
Glenmark Pharmaceuticals
Carlsbad Tech
GlaxoSmithKline PLC
Zydus Cadila
Epi Health LLC
Viatris Inc.
Apotex Inc.
Teva Pharmaceuticals Industries Ltd.
Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rise in prevalence of infections of the herpes simplex virus
- Social stigma about sexually transmitted diseases (STDs)
- Increase in demand for safe and effective HSV therapeutics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Acyclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Valacyclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Famciclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

5. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Geography, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)

7. Competitive Landscape

Fresenius SE & Co. KgaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Carlsbad Tech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Epi Health LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views